Partner with Allotar.
Allotar collaborates with pharmaceutical companies, research institutions, and strategic investors to accelerate the discovery and optimization of novel therapeutics.
Why Partner with Allotar
Less compute than enhanced sampling
Versus established workflows such as replica-exchange umbrella sampling applied to the same protein
Allosteric site accuracy
Benchmarked across diverse protein families with interpretable AI
Designed for the target site
Small molecules, macrocyclic peptides and computationally designed scaffolds
Self-improving loop
Every outcome, hit or miss, sharpens the model and seeds the next cycle
Partnering to Advance Precision Therapeutics
Allotar is an asset-driven discovery company advancing a focused pipeline through physics-based modeling and AI-guided design. We collaborate with pharmaceutical partners, biotech innovators, and investors to unlock high-value targets and accelerate the development of differentiated therapeutics.
Drug Discovery Partnerships
Apply AllotarX™ to priority targets using dynamics-driven modeling and selectivity-focused design to accelerate and de-risk discovery.
Pipeline Access & Licensing
Engage with internally developed programs at key inflection points for co-development, licensing, or strategic partnership.
Strategic Investment
Support the advancement of a scalable discovery platform and a growing pipeline targeting complex, underserved biology.
Start a Conversation
Tell us more about your partnership interests
Pittsburgh, PA & Austin, TX
contact@allotar.com

